The combined actions of these two agents increase Bax expression, inhibit Bcl-2 levels, and downregulate the phosphorylation of ERK and Akt, collectively suppressing prostate cancer progression and promoting apoptosis. The gene discussed is AKT1; the disease is Familial prostate cancer.